The Experts below are selected from a list of 3171 Experts worldwide ranked by ideXlab platform

A S Luchko - One of the best experts on this subject based on the ideXlab platform.

  • new approaches to prophylaxis of Endometrium Hyperplasia relaps in premenopausal women
    Reproductive Endocrinology, 2021
    Co-Authors: V O Beniuk, V H Ginzburg, D O Govsieiev, V F Oleshko, T V Kovaliuk, Yu V Kravchenko, A S Luchko
    Abstract:

    Research aim: to evaluate the effectiveness of therapy aimed at preventing endometrial Hyperplasia recurrence in premenopausal women.Materials and methods. Clinical and paraclinical examinations of 76 premenopausal women were carried out. Transvaginal ultrasound was performed, levels of estradiol, progesterone, homocysteine, folic acid, serum HOMA index evaluated, body mass index and blood pressure assessed. Women were divided into two groups after histological results obtained: the main group included 40 women who received oral progestins (dydrogesterone 10 mg) twice a day in combination with Depapilin® 395 mg twice a day; the comparison group included 36 women who received only oral progestins (dydrogesterone 10 mg) twice a day. Comparison of the therapy effectiveness was performed 6 and 9 months after the start of treatment.Results. Endometrial thickness stabilized within 9 months in women of the main group, and was within the physiological norm (before treatment – 22 ± 3.1 mm, 6 months after the start of treatment – 8,3 ± 0.46 mm, after 9 months – 9,7 ± 0.31 mm, p <0.05). The positive treatment effect consisted in a significant decrease in the frequency of endometrial Hyperplasia recurrence, which was 17 (17.5%) cases in the main group and 16 (44.4%) cases in the comparison group (p <0.05). Women of the main group also showed stable normalization of the level of estrogen and progesterone, a steady decrease in the level of homocysteine and a synergistic increase in the level of folic acid, normalization of blood pressure and reduction of body mass index.Conclusions. Depapilin® inclusion in the basic therapy of endometrial Hyperplasia in premenopausal aged women is pathogenetically justified due to the complex effect of the drug components on the extragonadal estrogens synthesis and the antiproliferative effect on the Endometrium.

  • New approaches to prophylaxis of Endometrium Hyperplasia relaps in premenopausal women
    'Publishing Office TRILIST', 2021
    Co-Authors: V O Beniuk, V H Ginzburg, D O Govsieiev, V F Oleshko, T V Kovaliuk, Yu V Kravchenko, A S Luchko
    Abstract:

    Research aim: to evaluate the effectiveness of therapy aimed at preventing endometrial Hyperplasia recurrence in premenopausal women. Materials and methods. Clinical and paraclinical examinations of 76 premenopausal women were carried out. Transvaginal ultrasound was performed, levels of estradiol, progesterone, homocysteine, folic acid, serum HOMA index evaluated, body mass index and blood pressure assessed. Women were divided into two groups after histological results obtained: the main group included 40 women who received oral progestins (dydrogesterone 10 mg) twice a day in combination with Depapilin® 395 mg twice a day; the comparison group included 36 women who received only oral progestins (dydrogesterone 10 mg) twice a day. Comparison of the therapy effectiveness was performed 6 and 9 months after the start of treatment. Results. Endometrial thickness stabilized within 9 months in women of the main group, and was within the physiological norm (before treatment – 22 ± 3.1 mm, 6 months after the start of treatment – 8,3 ± 0.46 mm, after 9 months – 9,7 ± 0.31 mm, p

V O Beniuk - One of the best experts on this subject based on the ideXlab platform.

  • new approaches to prophylaxis of Endometrium Hyperplasia relaps in premenopausal women
    Reproductive Endocrinology, 2021
    Co-Authors: V O Beniuk, V H Ginzburg, D O Govsieiev, V F Oleshko, T V Kovaliuk, Yu V Kravchenko, A S Luchko
    Abstract:

    Research aim: to evaluate the effectiveness of therapy aimed at preventing endometrial Hyperplasia recurrence in premenopausal women.Materials and methods. Clinical and paraclinical examinations of 76 premenopausal women were carried out. Transvaginal ultrasound was performed, levels of estradiol, progesterone, homocysteine, folic acid, serum HOMA index evaluated, body mass index and blood pressure assessed. Women were divided into two groups after histological results obtained: the main group included 40 women who received oral progestins (dydrogesterone 10 mg) twice a day in combination with Depapilin® 395 mg twice a day; the comparison group included 36 women who received only oral progestins (dydrogesterone 10 mg) twice a day. Comparison of the therapy effectiveness was performed 6 and 9 months after the start of treatment.Results. Endometrial thickness stabilized within 9 months in women of the main group, and was within the physiological norm (before treatment – 22 ± 3.1 mm, 6 months after the start of treatment – 8,3 ± 0.46 mm, after 9 months – 9,7 ± 0.31 mm, p <0.05). The positive treatment effect consisted in a significant decrease in the frequency of endometrial Hyperplasia recurrence, which was 17 (17.5%) cases in the main group and 16 (44.4%) cases in the comparison group (p <0.05). Women of the main group also showed stable normalization of the level of estrogen and progesterone, a steady decrease in the level of homocysteine and a synergistic increase in the level of folic acid, normalization of blood pressure and reduction of body mass index.Conclusions. Depapilin® inclusion in the basic therapy of endometrial Hyperplasia in premenopausal aged women is pathogenetically justified due to the complex effect of the drug components on the extragonadal estrogens synthesis and the antiproliferative effect on the Endometrium.

  • New approaches to prophylaxis of Endometrium Hyperplasia relaps in premenopausal women
    'Publishing Office TRILIST', 2021
    Co-Authors: V O Beniuk, V H Ginzburg, D O Govsieiev, V F Oleshko, T V Kovaliuk, Yu V Kravchenko, A S Luchko
    Abstract:

    Research aim: to evaluate the effectiveness of therapy aimed at preventing endometrial Hyperplasia recurrence in premenopausal women. Materials and methods. Clinical and paraclinical examinations of 76 premenopausal women were carried out. Transvaginal ultrasound was performed, levels of estradiol, progesterone, homocysteine, folic acid, serum HOMA index evaluated, body mass index and blood pressure assessed. Women were divided into two groups after histological results obtained: the main group included 40 women who received oral progestins (dydrogesterone 10 mg) twice a day in combination with Depapilin® 395 mg twice a day; the comparison group included 36 women who received only oral progestins (dydrogesterone 10 mg) twice a day. Comparison of the therapy effectiveness was performed 6 and 9 months after the start of treatment. Results. Endometrial thickness stabilized within 9 months in women of the main group, and was within the physiological norm (before treatment – 22 ± 3.1 mm, 6 months after the start of treatment – 8,3 ± 0.46 mm, after 9 months – 9,7 ± 0.31 mm, p

Hironobu Sasano - One of the best experts on this subject based on the ideXlab platform.

  • 17β hydroxysteroid dehydrogenases in human Endometrium and its disorders
    Molecular and Cellular Endocrinology, 2006
    Co-Authors: Kiyoshi Ito, Hiroki Utsunomiya, Takashi Suzuki, Sumika Saitou, Junichi Akahira, Kunihiro Okamura, Nobuo Yaegashi, Hironobu Sasano
    Abstract:

    In situ estrogen metabolism and synthesis have been considered to play a very important role in the development and progression of human endometrial carcinoma. 17Beta-hydroxysteroid dehydrogenases (17-HSDs) are enzymes involved in the formation of active sex steroids, including testosterone, estrone (E1) and estradiol (E2). Estrogens are interchanged by two enzymes, 17-HSD types 1 and 2, type 1 converts E1 to E2, and type 2 does reverse actions. 17-HSD type 5 catalyzes the reduction of androstenedione to testosterone. 17-HSD type 2 expression was decreased through normal Endometrium, Hyperplasia and carcinoma accordingly. There was a significant inverse correlation between intratumoral E2 concentration and the level of 17-HSD type 2 mRNA in endometrial carcinoma. 17-HSD type 5 expression was significantly increased through normal Endometrium, Hyperplasia and carcinoma accordingly. These results indicated that 17-HSD types 2 and 5 play an important role in the regulation of in situ estrogen production in endometrial carcinoma.

V H Ginzburg - One of the best experts on this subject based on the ideXlab platform.

  • new approaches to prophylaxis of Endometrium Hyperplasia relaps in premenopausal women
    Reproductive Endocrinology, 2021
    Co-Authors: V O Beniuk, V H Ginzburg, D O Govsieiev, V F Oleshko, T V Kovaliuk, Yu V Kravchenko, A S Luchko
    Abstract:

    Research aim: to evaluate the effectiveness of therapy aimed at preventing endometrial Hyperplasia recurrence in premenopausal women.Materials and methods. Clinical and paraclinical examinations of 76 premenopausal women were carried out. Transvaginal ultrasound was performed, levels of estradiol, progesterone, homocysteine, folic acid, serum HOMA index evaluated, body mass index and blood pressure assessed. Women were divided into two groups after histological results obtained: the main group included 40 women who received oral progestins (dydrogesterone 10 mg) twice a day in combination with Depapilin® 395 mg twice a day; the comparison group included 36 women who received only oral progestins (dydrogesterone 10 mg) twice a day. Comparison of the therapy effectiveness was performed 6 and 9 months after the start of treatment.Results. Endometrial thickness stabilized within 9 months in women of the main group, and was within the physiological norm (before treatment – 22 ± 3.1 mm, 6 months after the start of treatment – 8,3 ± 0.46 mm, after 9 months – 9,7 ± 0.31 mm, p <0.05). The positive treatment effect consisted in a significant decrease in the frequency of endometrial Hyperplasia recurrence, which was 17 (17.5%) cases in the main group and 16 (44.4%) cases in the comparison group (p <0.05). Women of the main group also showed stable normalization of the level of estrogen and progesterone, a steady decrease in the level of homocysteine and a synergistic increase in the level of folic acid, normalization of blood pressure and reduction of body mass index.Conclusions. Depapilin® inclusion in the basic therapy of endometrial Hyperplasia in premenopausal aged women is pathogenetically justified due to the complex effect of the drug components on the extragonadal estrogens synthesis and the antiproliferative effect on the Endometrium.

  • New approaches to prophylaxis of Endometrium Hyperplasia relaps in premenopausal women
    'Publishing Office TRILIST', 2021
    Co-Authors: V O Beniuk, V H Ginzburg, D O Govsieiev, V F Oleshko, T V Kovaliuk, Yu V Kravchenko, A S Luchko
    Abstract:

    Research aim: to evaluate the effectiveness of therapy aimed at preventing endometrial Hyperplasia recurrence in premenopausal women. Materials and methods. Clinical and paraclinical examinations of 76 premenopausal women were carried out. Transvaginal ultrasound was performed, levels of estradiol, progesterone, homocysteine, folic acid, serum HOMA index evaluated, body mass index and blood pressure assessed. Women were divided into two groups after histological results obtained: the main group included 40 women who received oral progestins (dydrogesterone 10 mg) twice a day in combination with Depapilin® 395 mg twice a day; the comparison group included 36 women who received only oral progestins (dydrogesterone 10 mg) twice a day. Comparison of the therapy effectiveness was performed 6 and 9 months after the start of treatment. Results. Endometrial thickness stabilized within 9 months in women of the main group, and was within the physiological norm (before treatment – 22 ± 3.1 mm, 6 months after the start of treatment – 8,3 ± 0.46 mm, after 9 months – 9,7 ± 0.31 mm, p

D O Govsieiev - One of the best experts on this subject based on the ideXlab platform.

  • new approaches to prophylaxis of Endometrium Hyperplasia relaps in premenopausal women
    Reproductive Endocrinology, 2021
    Co-Authors: V O Beniuk, V H Ginzburg, D O Govsieiev, V F Oleshko, T V Kovaliuk, Yu V Kravchenko, A S Luchko
    Abstract:

    Research aim: to evaluate the effectiveness of therapy aimed at preventing endometrial Hyperplasia recurrence in premenopausal women.Materials and methods. Clinical and paraclinical examinations of 76 premenopausal women were carried out. Transvaginal ultrasound was performed, levels of estradiol, progesterone, homocysteine, folic acid, serum HOMA index evaluated, body mass index and blood pressure assessed. Women were divided into two groups after histological results obtained: the main group included 40 women who received oral progestins (dydrogesterone 10 mg) twice a day in combination with Depapilin® 395 mg twice a day; the comparison group included 36 women who received only oral progestins (dydrogesterone 10 mg) twice a day. Comparison of the therapy effectiveness was performed 6 and 9 months after the start of treatment.Results. Endometrial thickness stabilized within 9 months in women of the main group, and was within the physiological norm (before treatment – 22 ± 3.1 mm, 6 months after the start of treatment – 8,3 ± 0.46 mm, after 9 months – 9,7 ± 0.31 mm, p <0.05). The positive treatment effect consisted in a significant decrease in the frequency of endometrial Hyperplasia recurrence, which was 17 (17.5%) cases in the main group and 16 (44.4%) cases in the comparison group (p <0.05). Women of the main group also showed stable normalization of the level of estrogen and progesterone, a steady decrease in the level of homocysteine and a synergistic increase in the level of folic acid, normalization of blood pressure and reduction of body mass index.Conclusions. Depapilin® inclusion in the basic therapy of endometrial Hyperplasia in premenopausal aged women is pathogenetically justified due to the complex effect of the drug components on the extragonadal estrogens synthesis and the antiproliferative effect on the Endometrium.

  • New approaches to prophylaxis of Endometrium Hyperplasia relaps in premenopausal women
    'Publishing Office TRILIST', 2021
    Co-Authors: V O Beniuk, V H Ginzburg, D O Govsieiev, V F Oleshko, T V Kovaliuk, Yu V Kravchenko, A S Luchko
    Abstract:

    Research aim: to evaluate the effectiveness of therapy aimed at preventing endometrial Hyperplasia recurrence in premenopausal women. Materials and methods. Clinical and paraclinical examinations of 76 premenopausal women were carried out. Transvaginal ultrasound was performed, levels of estradiol, progesterone, homocysteine, folic acid, serum HOMA index evaluated, body mass index and blood pressure assessed. Women were divided into two groups after histological results obtained: the main group included 40 women who received oral progestins (dydrogesterone 10 mg) twice a day in combination with Depapilin® 395 mg twice a day; the comparison group included 36 women who received only oral progestins (dydrogesterone 10 mg) twice a day. Comparison of the therapy effectiveness was performed 6 and 9 months after the start of treatment. Results. Endometrial thickness stabilized within 9 months in women of the main group, and was within the physiological norm (before treatment – 22 ± 3.1 mm, 6 months after the start of treatment – 8,3 ± 0.46 mm, after 9 months – 9,7 ± 0.31 mm, p